Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 54

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 54
---
 novel product candidates that are important to our
business. We may in the future also license or purchase patents and patent applications owned or controlled by others. As of December
31, 2024 our patent portfolio included 151 issued patents, 4 PCT applications pending and 217 pending patent applications, including six
allowed patent applications, in the United States, Europe, Canada, Japan, Australia, China, South Korea, Russia, Mexico, India, Hong Kong,
Singapore, South Africa and the African Regional Intellectual Property Organization, or the ARIPO. Some of our earlier filed patents have
expired or are expected to expire between now and 2026, subject to patent term extensions and adjustments that may be available in certain
jurisdictions. When key patents covering our core technology expire, competitors and other third parties may be able to make competing
products and encroach on our market share.

It is possible that defects
of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect
to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we are unable to secure or maintain
patent protection with respect to our Alpha DaRT technology and any proprietary products and technology we develop, our business, financial
condition, results of operations, and prospects could be materially harmed. Our pending and future patent applications may not result
in patents being issued or that issued patents will afford sufficient protection of our product candidates or their intended uses against
competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated by third parties,
or effectively prevent others from commercializing competitive technologies, products or product candidates. Further, some of our pending
patent applications may be allowed in the future, but we cannot be certain that an allowed patent application will become an issued patent.
There may be events that cause withdrawal of the allowance of a patent application. For example, after a patent application has been allowed,
but prior to being issued, material that could be relevant to patentability may be identified. In such circumstances, the applicant may
pull the application from allowance in order for the USPTO to review the application in view of the new material. We cannot be certain
that the USPTO will issue the application in view of the new material. We anticipate additional patent applications will be filed both
in the United States and in other countries, as appropriate. However, we cannot predict: